SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT
                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934


        Date of Report (Date of earliest event reported): October 2, 2001


                          CELLEGY PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
             (Exact name of Registrant as specified in its charter)


                                   California
             ------------------------------------------------------
                 (State or other jurisdiction of incorporation)


         0-26372                                          82-0429727
----------------------------                       --------------------------
       (Commission                                      (IRS Employer
       File Number)                                     Identification No.)


    349 Oyster Point Boulevard, Suite 200
           South San Francisco, CA                             94080
----------------------------------------------------  --------------------------
   (Address of principal executive offices)                 (Zip Code)


                                 (650) 616-2200
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)


--------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)



ITEM 5: OTHER EVENTS.

         Filed with this report as Exhibit  99.01 is a press  release  issued by
the registrant on October 2, 2001,  announcing  preliminary results of a pivotal
Phase III clinical  trial  regarding  the  registrant's  lead drug,  Anogesic(R)
(nitroglycerin   ointment),   for  the   treatment  of  anal  fissures  and  the
registrant's  intention  to  submit  these  results  to the  U.S.  Food and Drug
Administration as an amendment to its NDA submission made in June 2001.

ITEM 7: FINANCIAL STATEMENTS AND EXHIBITS.

     (c)      Exhibits.
              --------

               99.01  Press Release issued by the Registrant on October 2, 2001.

                                      -2-


                                    SIGNATURE

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  October 4, 2001                   CELLEGY PHARMACEUTICALS, INC.


                                         By: /s/ Richard Juelis
                                             ------------------
                                             A. Richard Juelis
                                             Vice President, Finance and Chief
                                             Financial Officer

                                      -3-